Hugo Saavedra
CEO
Menu
Singapore’s Ministry of Health approves KYAN’s clinical laboratory license to provide the Optim.AI™ functional precision medicine test
KYAN Technologies, a pioneering leader in the field of functional precision medicine for oncology. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise.
Our revolutionary technology is a phenotypic response system that efficiently identifies safe and effective drug -dose combination therapies
Efficiently solves large and dynamic complex systems through a minimum number of tests
Prospective experiments that identify the optimal phenotypic response surface across different biological models
SAME treatment for all patients and most will fail, requiring multiple lines of treatment
SMALL chance that patients have identifiable biomarkers matched with therapy (est. < 10%)
LIMITED results when screening single drugs and preselected combinations
UNIQUE data and treatments for each patient’s as their own cancer cells are used for drug response analysis
VAST number of regimens are evaluated to maximize finding effective treatment, truly personalizing care
ALL actionable treatments within a drug set can be ranked based on sensitivity and compared, including against standard care
Large search discovery for new targets + combinations
Explore combination discovery for lead targets
Find biomarker signatures based on phenotypic response curves
Retrospective or prospective studies to support dose optimization within trials
Find new combination partners or companion Dx for assets that failed trials
Our ex vivo analytic platform, Optim.AI™, empowers oncologists to better guide treatment for patients with truly personalized results
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study
IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Artificial intelligence in cancer therapy
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma
Harnessing Artificial Intelligence to Optimize Long‐Term Maintenance Dosing for Antiretroviral‐Naive Adults with HIV‐1 Infection
Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine
Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
1 Research Link, #05-45, Singapore 117604.
KYAN Technologies is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory
HCI License Number:
L/23I0025/CLB/001/232
